Given the lack of innovation and over-reliance on existing products, I recommend a "sell" rating for Haleon, questioning its standalone success and justification for current valuation. GSK chose ...

The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...

GSK divested Haleon, its consumer group ... of 4% over the next five years (including joint ventures), with new products such as Shingrix and Arexvy offsetting generic competition due to patent ...

Haleon is a global consumer health company based in the UK, focused on developing and marketing over-the-counter health products. The company was formed as a spin-off from GSK (GlaxoSmithKline ...

Haleon, the two-year-old CPG spinoff from GSK, is not only leading in marketing ... Health & Wellness Index include two other pain relief products -- Advil and Voltaren – along with Theraflu.

Despite pressure on consumer spending, consumers prioritise trusted brands for their health-related needs and Haleon is a ...

GSK, its consumer health spin-off Haleon, and Sanofi could be on the ... Some voluntarily took their products off the market as soon as the NDMA finding was reported by the FDA.

The transition to next-gen lines of less harmful tobacco products is doing well ... forming the company Haleon. Like many pharma companies, GSK is at risk of legal action related to adverse ...

GSK Plc, Novartis AG, Royal Philips NV and Haleon Plc are also due ... buyback pace will be in focus after the company flagged weak oil-products trading in the third quarter and lower margins ...

LEMSIP and other popular cold and flu tablets should be pulled from Britain’s shelves because they don’t work, experts have ...